Evommune, Inc. stock analysis
Want to see EVMN full AI Analyst Report?
Evommune, Inc. (EVMN) Stock Price & Analysis
EVMN Stock Chart & Stats
- Day’s Range
- $6.77 - $7.19
- 52-Week Range
- $4.94 - $33.20
- Previous Close
- $7.10
- Volume
- N/A
- Average Volume (3M)
- 919.86K
- Market Cap
- $290.28M
- Enterprise Value
- $139.61M
- Total Cash (Recent Filing)
- $168.64M
- Total Debt (Recent Filing)
- $8.19M
- Price to Earnings (P/E)
- ―
- Beta
- 0.79
- Next Earnings
- Mar 11, 2027 (Est.)
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strengthened Balance Sheet
Very low leverage gives Evommune greater financial flexibility while it advances clinical programs. The strengthened capital structure can reduce near-term balance-sheet pressure and provide more capacity to absorb development setbacks or fund prioritized trials.
Promising EVO301 Clinical Signal
EVO301 has produced a meaningful controlled efficacy signal in atopic dermatitis, supported by favorable tolerability and biomarker evidence. Quarterly dosing potential and broad pathway activity could improve the asset's differentiation if confirmed in Phase 2b.
Expanding Immunology Pipeline
The combination of biologic and small-molecule programs across inflammatory and autoimmune diseases diversifies clinical catalysts beyond one asset. EVO570 also broadens the target biology and potential disease reach of Evommune's development platform.
Bears Say
No Current Revenue Base
Evommune currently lacks recurring operating revenue to offset research and development spending. This leaves financial progress dependent on clinical success, licensing activity, or external capital rather than an established commercial engine, increasing execution sensitivity.
Heavy Ongoing Cash Burn
Persistent negative operating and free cash flow means the company consumes substantial capital while its programs remain in development. Continued investment will likely require disciplined prioritization and may create future financing needs before products generate revenue.
EVO756 Atopic Dermatitis Failure
The failed Phase 2b study removes an indication from EVO756's development opportunity and shifts greater strategic importance to EVO301. It also demonstrates that the broader pipeline remains exposed to meaningful clinical and program-level execution risk.
Evommune, Inc. News
EVMN FAQ
What was Evommune, Inc.’s price range in the past 12 months?
What is Evommune, Inc.’s market cap?
When is Evommune, Inc.’s upcoming earnings report date?
How were Evommune, Inc.’s earnings last quarter?
Is Evommune, Inc. overvalued?
Does Evommune, Inc. pay dividends?
What is Evommune, Inc.’s EPS estimate?
How many shares outstanding does Evommune, Inc. have?
What happened to Evommune, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Evommune, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Evommune, Inc. Stock Smart Score
Company Description
Evommune, Inc.
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Luis C. Pena
- Employees
- 48
- Website
- www.evommune.com
- Address
- 1841 Page Mill Road, Palo Alto, CA, 94304, US
Evommune, Inc. (EVMN) Earnings & Revenues
EVMN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 6 | 12 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 2 | 0 | 10 |







